EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Q32 Bio's Enterprise Value is $245.49 Mil.
Q32 Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-40.65 Mil. Therefore, Q32 Bio's EV-to-EBIT for today is -6.04.
The historical rank and industry rank for Q32 Bio's EV-to-EBIT or its related term are showing as below:
QTTB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.27 Med: -4.56 Max: -2.62
Current: -6.04
During the past 3 years, the highest EV-to-EBIT of Q32 Bio was -2.62. The lowest was -8.27. And the median was -4.56.
QTTB's EV-to-EBIT is ranked worse than 100% of 423
companies
in the Biotechnology industry
Industry Median: 10.05
vs QTTB: -6.04
The historical data trend for Q32 Bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Q32 Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Q32 Bio's EV-to-EBIT falls into.
Q32 Bio's current Enterprise Value is $245.49 Mil.
Q32 Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q32 Bio (NAS:QTTB) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Q32 Bio's Enterprise Value for the quarter that ended in Mar. 2024 was $88.11 Mil.
Q32 Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q32 Bio EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Q32 Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QTTB has been successfully added to your